Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 791Xls
2D Structure
Also known as: Dabigatran etexilate mesylate, 872728-81-9, Pradaxa, Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid, Dtxsid20236248, Ex-a1966
Molecular Formula
C35H45N7O8S
Molecular Weight
723.8  g/mol
InChI Key
XETBXHPXHHOLOE-UHFFFAOYSA-N

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid
2.1.2 InChI
InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)
2.1.3 InChI Key
XETBXHPXHHOLOE-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCOC(=O)N=C(C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N.CS(=O)(=O)O
2.1.5 Isomeric SMILES
CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\N.CS(=O)(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Bibr 1048

2. Dabigatran

3. Dabigatran Etexilate

4. Dabigatran Etexilate Mesylate

5. Etexilate Mesylate, Dabigatran

6. Etexilate, Dabigatran

7. Mesylate, Dabigatran Etexilate

8. N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-beta-alanine

9. Pradaxa

2.2.2 Depositor-Supplied Synonyms

1. Dabigatran Etexilate Mesylate

2. 872728-81-9

3. Pradaxa

4. Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic Acid

5. Dtxsid20236248

6. Ex-a1966

7. Mfcd25424070

8. S5960

9. Ccg-213236

10. Cs-w004358

11. (z)-ethyl 3-(2-(((4-(n'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoate Methanesulfonate

12. 728p819

2.3 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 723.8 g/mol
Molecular Formula C35H45N7O8S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count11
Rotatable Bond Count17
Exact Mass723.30503259 g/mol
Monoisotopic Mass723.30503259 g/mol
Topological Polar Surface Area217 Ų
Heavy Atom Count51
Formal Charge0
Complexity1100
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NamePradaxa
PubMed HealthDabigatran (By mouth)
Drug ClassesAnticoagulant
Drug LabelThe chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo...
Active IngredientDabigatran etexilate mesylate
Dosage FormCapsule
RouteOral
Strengtheq 150mg base; eq 75mg base
Market StatusPrescription
CompanyBoehringer Ingelheim

2 of 2  
Drug NamePradaxa
PubMed HealthDabigatran (By mouth)
Drug ClassesAnticoagulant
Drug LabelThe chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo...
Active IngredientDabigatran etexilate mesylate
Dosage FormCapsule
RouteOral
Strengtheq 150mg base; eq 75mg base
Market StatusPrescription
CompanyBoehringer Ingelheim

4.2 Drug Indication

Pradaxa 75 mg

- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Pradaxa 110 mg

- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.

- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Pradaxa 150 mg

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.

- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antithrombins

Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Thrombin Inhibitors [MoA]; Direct Thrombin Inhibitor [EPC]
5.3 ATC Code

B01AE07